About the Center for Drug Evaluation and Research > Peginterferon alfa-2b

U. S. Food and Drug Administration approved peginterferon alfa-2b (Sylatron, Schering Corporation, Kenilworth, NJ 07033), for the treatment of patients with melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy. (March 29, 2011) More Information: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm249263.htm


About the Center for Drug Evaluation and Research > Peginterferon alfa-2b